MARKET

PCVX

PCVX

Vaxcyte, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.78
-0.40
-1.53%
After Hours: 25.78 0 0.00% 16:00 09/24 EDT
OPEN
25.81
PREV CLOSE
26.18
HIGH
26.43
LOW
25.21
VOLUME
89.83K
TURNOVER
--
52 WEEK HIGH
55.93
52 WEEK LOW
15.51
MARKET CAP
1.21B
P/E (TTM)
-15.2274
1D
5D
1M
3M
1Y
5Y
Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that C...
GlobeNewswire · 5d ago
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 09/13 14:35
SLI, XAIR, MBII among mid-day movers
Gainers: PharmaCyte Biotech (NASDAQ:PMCB) +118%. Virpax Pharmaceuticals (NASDAQ:VRPX) +59%. SGOCO Group (NASDAQ:SGOC) +53%. AzurRx BioPharma (NASDAQ:AZRX) +30%. NRx Pharmaceuticals (NASDAQ:NRXP) +26%. Standard Lithium (NYSE:SLI) +21%. ESSA Pharma (NASDAQ:E...
Seekingalpha · 08/18 16:43
34 Stocks Moving In Wednesday's Mid-Day Session
Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 139% to $8.18 after surging over 15% on Tuesday.
Benzinga · 08/18 16:00
BRIEF-Vaxcyte Posts Quarterly Loss Per Share Of $0.46
reuters.com · 08/11 21:21
BRIEF-Vaxcyte Announced Additional Award Of $3.2 Mln From CARB-X To Advance Development Of VAX-A1
reuters.com · 08/05 14:36
Vaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections
-- Award Commits an Additional $3.2 Million in Funding; Total Potential Funding of $29.7 Million Based on Future Milestones --
GlobeNewswire · 08/05 12:30
10 Stocks to Buy According to Neil Shahrestani’s Ikarian Capital
In this article, we will take a look at the 10 stocks to buy according to Neil Shahrestani’s Ikarian Capital. To skip our detailed analysis of Shahrestani’s history, hedge fund performance, and investment philosophy, go directly to the 5 Stocks to Buy Acco...
Insider Monkey · 08/03 13:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PCVX. Analyze the recent business situations of Vaxcyte, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PCVX stock price target is 50.50 with a high estimate of 55.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 86
Institutional Holdings: 43.24M
% Owned: 92.48%
Shares Outstanding: 46.76M
TypeInstitutionsShares
Increased
35
1.15M
New
12
306.39K
Decreased
16
830.18K
Sold Out
11
1.42M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Kurt Von Emster
President/Chief Financial Officer
Andrew Guggenhime
Chief Executive Officer/Co-Founder/Director
Grant Pickering
Co-Founder/Vice President
Jeff Fairman
Chief Operating Officer
Jim Wassil
Senior Vice President
Paul Sauer
Chief Compliance Officer/General Counsel/Secretary
Jane Wright-Mitchell
Director
Halley Gilbert
Director
Peter Hirth
Director
Heath Lukatch
Independent Director
Annie Drapeau
Independent Director
Teri Loxam
No Data
About PCVX
Vaxcyte Inc. is a vaccine company. The Company is focused on developing vaccines designed to prevent or treat common and deadly infectious diseases worldwide. Its cell-free protein synthesis platform enables it to design and produce protein carriers and antigens. Its pipeline includes pneumococcal conjugate vaccine (PCV) candidates. Its lead vaccine candidate is VAX-24, a 24-valent investigational PCV. Its pipeline also includes VAX-XP, VAX-A1 and VAX-PG. The Company's second PCV, VAX-XP, uses its modular platform and builds on the technical proof of concept established by VAX-24. VAX-A1 is a conjugate vaccine being developed for group A strep infections. VAX-PG is being developed as a protein vaccine for the treatment of periodontitis.

Webull offers kinds of Vaxcyte Inc stock information, including NASDAQ:PCVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCVX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PCVX stock methods without spending real money on the virtual paper trading platform.